ReviewFrontiers in immunology2018
Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- The mevalonate and methylerythritol phosphate pathways as therapeutic targets in protozoan parasites: from moonlighting enzymes to metabolic plasticity.Cell communication and signaling : CCS · 2026Review
- γδ T Cells in Autoinflammatory Diseases.Cells · 2026Review
- Whole-genome resequencing of the Kazakh coarse-wool fat-tailed sheep identifies functional variants in disease-associated genes.Frontiers in veterinary science · 2026Article
- Diester Prodrugs of a Phosphonate Butyrophilin Ligand Display Improved Cell Potency, Plasma Stability, and Payload Internalization.Journal of medicinal chemistry · 2023Article
- Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment.Molecular cancer · 2023Review
- BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment.International journal of molecular sciences · 2022Review
- The antitumor activity of human Vγ9Vδ2 T cells is impaired by TGF-β through significant phenotype, transcriptomic and metabolic changes.Frontiers in immunology · 2022Article
- Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.International journal of molecular sciences · 2021Review
- Potent double prodrug forms of synthetic phosphoantigens.Bioorganic & medicinal chemistry · 2020Article
- Fetal public Vγ9Vδ2 T cells expand and gain potent cytotoxic functions early after birth.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies.Nature reviews. Drug discovery · 2020Review
- The Nonmevalonate Pathway of Isoprenoid Biosynthesis Supports Anaerobic Growth of Listeria monocytogenes.Infection and immunity · 2020Article
- Topology and expressed repertoire of the Felis catus T cell receptor loci.BMC genomics · 2020Article
- Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.Frontiers in immunology · 2020Article
- Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells.Frontiers in immunology · 2020Review
- A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.Biochemical pharmacology · 2019Article
- Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs.ChemMedChem · 2019Article
- A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.Biochemical pharmacology · 2018Article
- Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.Journal of medicinal chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vγ9Vδ2 T cells represent a major unconventional γδ T cell subset located in the peripheral blood of adults in humans and several non-human primates. Lymphocytes that constitute this transitional subset can sense subtle level changes of intracellular phosphorylated intermediates of the isoprenoid biosynthesis pathway (phosphoantigens, pAg), such as isopentenyl pyrophosphate, during cell stress events. This unique antigenic activation process operates in a rigorous framework that requires the expression of butyrophilin 3A1 (BTN3A1/CD277) molecules, which are type I glycoproteins that belong to the B7 family. Several studies have further shown that pAg specifically bind to the intracellular B30.2 domain of BTN3A1 linked to the antigenic activation of Vγ9Vδ2 T cells. Here, we highlight the recent advances in BTN3A1 dynamics induced upon the binding of pAg and the contribution of the different subunits to this activation process. Recent reports support that conformational modifications of BTN3A1 might represent a key step in the detection of infection or tumorigenesis by Vγ9Vδ2 T cells. A better understanding of this mechanism will help optimize novel immunotherapeutical approaches that target defined functions of this unique γδ T cell subset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.